Medicenna Therapeutics Corp. MDNAF
Set alert
0.31 USD -0.02 -4.69%
As of Nov 3, 12:25 PM ET
0.304 Day range 0.305
0.229 52-week range 1.30
- YTD
- -54.88%
- 1 year
- -71.23%
- Open
- 0.304
- Prev close
- 0.32
- Mkt cap
- 28.15M
- Vol
- 5.50K
- Avg vol
- 43.61K
- EPS
- -0.16
- P/E
- 0.00
More statistics
- Low
- 0.304
- High
- 0.305
2Y chart
Signals (79)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 2026 | 4 hours ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 4 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| RSI: Overbought | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
Newest 20 of 79.
Financials — quick view
MDNAF Revenue — quarterly 0
MDNAF Net income — quarterly -2.86M
MDNAF EPS — quarterly -0.04
News
- Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
- Medicenna Announces Results of Annual General and Special Meeting of Shareholders
- Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
- Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
- Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
- Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
- Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
- Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- Medicenna Announces the Launch of a Marketed Public Offering of Securities
Your note
Sign in to keep a note on MDNAF — it syncs with the Stock Master app.